Back to Trial

Oracle Runs

Oracle findings and outcome history for Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases (NCT06777433).

Runs
2
Findings
2
Latest Run
Apr 2, 2026, 5:14 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/3/26 UTC
Executive Summary

Public trial-specific interim readouts are clearly favorable. Sponsor-distributed coverage says this Phase 2b study achieved its primary endpoint in 90% of evaluable patients, with encouraging secondary signals. Oncology media also described prior interim data from the same NCT as positive and confidence-strengthening.

Sources
Sponsorseekingalpha.com3/24/26
Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

Company announcement: 90% (18/20) achieved PET-MRI concordance, the primary endpoint; tumor uptake was significant/selective, and early sensitivity/specificity trends were described as encouraging.

View source
Web Searchcancernetwork.com
RAD 101 Imaging Agent Achieves Concordance with MRI in Suspected Brain Mets

CancerNetwork summarized this exact Phase 2b trial as having “positive interim results”; 11/12 patients achieved concordance, and the CEO said the data strengthened confidence in phase 2 success.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted92% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Public trial-specific interim readouts are clearly favorable. Sponsor-distributed coverage says this Phase 2b study achieved its primary endpoint in 90% of evaluable patients, with encouraging secondary signals. Oncology media also described prior interim data from the same NCT as positive and confidence-strengthening.

Found Apr 2, 2026, 5:14 PMOutcome date Mar 24, 2026, 11:00 AMReviewed Apr 3, 2026, 5:19 PM
Sponsorseekingalpha.comMar 24, 2026, 11:00 AM
Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
Company announcement: 90% (18/20) achieved PET-MRI concordance, the primary endpoint; tumor uptake was significant/selective, and early sensitivity/specificity trends were described as encouraging.
Web Searchcancernetwork.com
RAD 101 Imaging Agent Achieves Concordance with MRI in Suspected Brain Mets
CancerNetwork summarized this exact Phase 2b trial as having “positive interim results”; 11/12 patients achieved concordance, and the CEO said the data strengthened confidence in phase 2 success.
NO_DECISIONDismissed88% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Found a clearly positive interim sponsor update for this exact Phase 2b study, but not a final overall readout. The trial is still listed as active/recruiting, so the public evidence is incomplete and not sufficient to label the full study definitively positive or negative.

Found Mar 31, 2026, 9:43 PMReviewed Apr 1, 2026, 6:34 AM
Sponsorstocktitan.netMar 24, 2026, 12:00 AM
Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
Sponsor-announced second interim data: 18/20 evaluable patients achieved the primary endpoint, and the company framed the findings as achieving the endpoint in this Phase 2b trial.
Sponsorradiopharmtheranostics.com
Clinical Trials – Radiopharm Theranostics
Sponsor trial listing for NCT06777433 shows the Phase 2b RAD101 brain metastases study as Active, recruiting, indicating no final completed readout yet.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle ReviewApr 3, 2026, 5:19 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)92% confidenceReviewed Apr 3, 2026, 5:19 PM

Public trial-specific interim readouts are clearly favorable. Sponsor-distributed coverage says this Phase 2b study achieved its primary endpoint in 90% of evaluable patients, with encouraging secondary signals. Oncology media also described prior interim data from the same NCT as positive and confidence-strengthening.